However, our interdisciplinary approach combining clinical, radiological, and immunohistochemical characteristics highlight a potential protective metabolic adaptation in CAD and suggest that EAT may serve as both a biomarker and a therapeutic target, particularly for incretin-based strategies [37]. The gene discussed is GCG; the disease is coronary artery disorder.